Cover Image
市場調查報告書

腸胃治療藥及診斷:技術及全球市場

Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets

出版商 BCC Research 商品編碼 372632
出版日期 內容資訊 英文 173 Pages
訂單完成後即時交付
價格
Back to Top
腸胃治療藥及診斷:技術及全球市場 Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
出版日期: 2016年09月30日 內容資訊: 英文 173 Pages
簡介

全球腸胃疾病治療藥及診斷市場2015年達496億美元。該市場預計至2021年以年複合成長率4.3%擴大,預計達638億美元。

本報告提供全球腸胃疾病治療藥及診斷市場相關調查,市場概要與至2021年的預測,產業趨勢,市場機會,及產業的主要參與企業簡介彙整。

第1章 簡介

第2章 摘要整理

第3章 概要

  • 胃癌
  • 發炎性腸道疾病
  • 便秘
  • 類鴉片物質誘發性便秘
  • 胃食道逆流症

第4章 病因

  • 腸胃系統的解剖和生理學
  • 腸胃系統結構
  • 跟其他系統的相互作用
  • 腸神經系統:概要
  • 腸胃系統的功能的影響因素
  • 腸胃系統的生理學和腸胃流程的各部位功能
  • 消化
  • 吸收
  • 排除
  • 腸胃系統組織
  • 腸胃管疾病和特異
  • 腸胃管牆的疾病
  • 發炎性腸道疾病 其他

第5章 處方藥市場

  • 止瀉劑
  • 胃癌治療
  • 胃食道逆流症治療
  • 其他藥劑

第6章 OTC藥市場

  • 製酸藥
  • 局部作用的止瀉
  • 質子幫浦抑制劑

第7章 診斷和設備市場

  • 腸疾病檢驗方法
  • 腸診斷檢驗市場
  • 曲狀桿菌
  • 諾羅病毒
  • 輪狀病毒 其他

第8章 腸胃系統產品平台

  • 胃癌治療藥
  • 胃食道逆流症及消化性潰瘍
  • 潰瘍性大腸炎及克隆氏症的治療藥

第9章 專利

第10章 企業簡介

圖表

目錄
Product Code: PHM046C

REPORT HIGHLIGHTS

The global market for gastrointestinal disorder therapeutics and diagnostics reached $49.6 billion in 2015. This market is expected to grow from nearly $51.8 billion in 2016 to $63.8 billion in 2021 at a compound annual growth rate of 4.3% from 2016-2021.

This report provides:

  • An overview of the global markets for gastrointestinal therapeutics and diagnostics.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
  • Analyses of therapeutics currently on the market as well as potential products and classes of products that are likely to have a significant impact.
  • Descriptions of the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future.
  • Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities.
  • Profiles of major players in the industry.

SCOPE OF REPORT

This report is designed to provide an in-depth look at the therapeutic and diagnostic options of various gastrointestinal disorders. The geographic scope of the report is global, with particular emphasis on the key markets such as the U.S. and the European Union Five (EU5). The estimated market data is also global in nature, with geographic segments such as the U.S., EU and Rest of the World (ROW). The report provides a brief overview of the gastrointestinal system, which provides an introduction to the disorders of the gastrointestinal system; cites risk factors, where applicable; presents current pharmaceutical treatments, market size and key market participants (both prescription and OTC); and presents potential treatments in R&D, potential market size and future market entrants.

As already mentioned, the market for gastrointestinal pharmaceuticals is divided into two general segments: prescription gastrointestinal pharmaceuticals and OTC gastrointestinal pharmaceuticals. Similarly, the market for gastrointestinal diagnostics, testing and vaccines is divided into three general segments:

  • Diagnostics and testing market.
  • Medical devices (endoscopy)
  • Vaccines.

The market is further broken down into the drugs to treat specific disorders within the gastrointestinal system, including the following:

  • Gastrointestinal tract disorders.
  • Gastrointestinal tract walls disorders.
  • Gastrointestinal motility disorders.
  • Gastrointestinal cancers.

Each sub-segment is covered in detail, describing the disorders and diseases, identifying currently available and potential products, and competitors.

ANALYST'S CREDENTIALS

Yogita Zutshi has 15 years of industry experience working in the areas of clinical operations, medical/regulatory writing and market research experience in the pharmaceutical domain. She has an MS in Clinical Research, an MS in Organic Chemistry, and a Bachelor's degree in Education. She has also worked on research projects in Clinical Data Management (CDM), and has developed training modules for the clinical and pharmacovigilance areas. She has a high level of proficiency in customized market topline studies, secondary market research and competitive intelligence.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF REPORT
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS
  • ANTIDIARRHEALS
  • ANTIEMETICS
  • GASTRIC CANCER
  • GASTROESOPHAGEAL REFLUX DISEASE TREATMENTS
  • LAXATIVES
  • INFLAMMATORY BOWEL DISEASES
  • OTHER GI DRUGS
  • SUMMARY TABLE GLOBAL MARKET FOR GASTROINTESTINAL DISORDER THERAPEUTICS AND DIAGNOSTICS, BY CATEGORY, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR GASTROINTESTINAL DISORDER THERAPEUTICS AND DIAGNOSTICS, BY CATEGORY, 2015-2021 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • TABLE 1: U.S. INCIDENCE OF INDIVIDUAL PATHOGENS
  • TABLE 2: ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GI CONDITIONS IN THE U.S.
  • GASTRIC CANCER
    • TABLE 3: GASTRIC CANCER PREVALENCE, 2012-2021 (THOUSANDS)
  • INFLAMMATORY BOWEL DISEASE (IBD)
    • TABLE 4: PREVALENCE ESTIMATES OF IBD, BY COUNTRY (%)
    • TABLE 5: U.S. PREVALENCE OF INFLAMMATORY BOWEL DISEASE (NUMBER OF CASES PER 100,000 POPULATION)
    • TABLE 6: U.S. INCIDENCE OF INFLAMMATORY BOWEL DISEASE (NUMBER OF NEWLY DIAGNOSED CASES PER 100,000 PERSON-YEARS)
    • TABLE 7: GLOBAL PREVALENCE OF INFLAMMATORY BOWEL DISEASE
  • CONSTIPATION
  • OPIOID-INDUCED CONSTIPATION
    • TABLE 8: COMMONLY USED LAXATIVE AGENTS
  • GASTROESOPHAGEAL REFLUX DISEASE
    • TABLE 9: PREVALENCE OF GERD SYMPTOMS (%)

CHAPTER 4 - ETIOLOGY

  • ANATOMY AND PHYSIOLOGY OF THE GASTROINTESTINAL SYSTEM
  • STRUCTURE OF GI SYSTEM
  • INTERACTIONS WITH OTHER SYSTEMS
    • Nervous System
  • THE ENTERIC NERVOUS SYSTEM: AN OVERVIEW
  • FACTORS AFFECTING THE FUNCTIONING OF THE GI SYSTEM
  • PHYSIOLOGY OF THE GI SYSTEM AND THE ROLE OF EACH PART IN THE GI PROCESS
    • INGESTION AND DEGLUTITION
      • Mouth
      • Pharynx
      • Esophagus
    • DIGESTION
      • Mouth
      • Stomach
      • Small Intestines
    • ABSORPTION
    • ELIMINATION
      • Large Intestine
    • ORGANS OF THE GASTROINTESTINAL SYSTEM
      • Liver
      • Biliary Tract
      • Pancreas
    • DISORDERS AND ANOMALIES OF THE GI TRACT
      • Dysphagia
      • Esophageal Pain
      • Abdominal Pain
      • Constipation
      • Diarrhea
    • DISORDERS OF THE GASTROINTESTINAL TRACT WALLS
      • Gastritis
      • Gastroenteritis
      • Peptic Ulcers
      • Gastric Ulcers
      • Duodenal Ulcers
    • INFLAMMATORY BOWEL DISEASE
      • Ulcerative Colitis
      • Crohn's Disease
      • Enterocolitis
    • DIVERTICULAR DISEASE
    • ANOMALIES GASTROINTESTINAL TRACT MOTILITY
      • Irritable Bowel Syndrome
      • Intestinal Obstructions
    • DISORDERS RELATED TO GASTROINTESTINAL MALABSORPTION
      • Celiac Sprue
      • Tropical Sprue
    • CANCERS OF THE GASTROINTESTINAL SYSTEM
      • Esophageal Cancer
      • Gastric Cancer
      • Liver Cancer
      • Pancreatic Cancer
      • Small Intestinal Cancer
      • Colonic Polyps and Colon Cancer
    • LATEST TREATMENT AND PROGNOSIS METHODS FOR CANCER OF THE GI SYSTEM
    • PILL-SIZED VIDEO CAMERA: PILLCAM ESO
      • SmartPill
      • Monoclonal Antibodies
    • INSURANCE COVERAGE FOR TREATMENT
      • TABLE 10: U.S. STATES THAT PROVIDE COMPLETE RANGE OF COLORECTAL DIAGNOSTIC SCREENING
    • LATEST RESEARCH TRENDS AND STUDIES IN GASTROINTESTINAL FIELD
      • Radio Frequency Identification Technology
      • Generic Influence and Penetration
  • BRANDED VS. OTC PROTON PUMP INHIBITORS
  • MAIL ORDER TRENDS
  • MOBILE APPLICATION

CHAPTER 5 - PRESCRIPTION THERAPY MARKET

  • TABLE 11: GLOBAL MARKET FOR PRESCRIPTION GI THERAPIES, BY CATEGORY, THROUGH 2021 ($ MILLIONS)
  • ANTIDIARRHEALS
    • SYSTEMICALLY ACTING ANTIDIARRHEALS
    • OPIUM DERIVATIVES
      • TABLE 12: KEY ANTI-DIARRHEAL BRANDS
    • MARKET SIZE AND GROWTH
      • TABLE 13: GLOBAL MARKET FOR PRESCRIPTION ANTIDIARRHEAL THERAPIES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 1: GLOBAL MARKET FOR PRESCRIPTION ANTIDIARRHEAL THERAPIES, BY REGION, 2015-2021 ($ MILLIONS)
    • ANTIEMETICS
      • TABLE 14: ANTIEMETICS: SITE OF ACTION AND EXAMPLES
    • LOCALLY ACTING ANTIEMETICS
    • CENTRALLY ACTING ANTIEMETICS
      • Antidopaminergics
        • Phenothiazines
        • Metochlopramide
    • ANTICHOLINERGICS
    • SEROTONIN RECEPTOR ANTAGONISTS
      • Neurokinin-1 Receptor Antagonists
    • MISCELLANEOUS ANTIEMETICS
      • TABLE 15: MARKETED ANTIEMETIC PRODUCTS
    • MARKET SIZE AND GROWTH
      • TABLE 16: GLOBAL MARKET FOR PRESCRIPTION ANTIEMETIC THERAPIES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 2: GLOBAL MARKET FOR PRESCRIPTION ANTIEMETIC THERAPIES, BY REGION, 2015-2021 ($ MILLIONS)
  • GASTROINTESTINAL CANCER TREATMENTS
    • BIOLOGICS
      • TABLE 17: MARKETED GASTROINTESTINAL CANCER PRODUCTS
    • MARKET SIZE AND GROWTH
      • TABLE 18: GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER THERAPIES, BY REGION, THROUGH 2021 ($ MILLIONS
      • FIGURE 3: GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER THERAPIES, BY REGION, 2015-2021 ($ MILLIONS)
  • GASTROESOPHAGEAL REFLUX DISEASE TREATMENTS
    • H2 INHIBITORS
      • TABLE 19: MARKETED H2 INHIBITOR PRODUCTS
    • MARKET SIZE AND GROWTH
      • TABLE 20: GLOBAL PRESCRIPTION H2 INHIBITOR MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 4: GLOBAL PRESCRIPTION H2 INHIBITOR MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • PROTON PUMP INHIBITORS
      • TABLE 21: PROTON PUMP INHIBITORS: THERAPY AND PH
      • TABLE 22: MARKETED PROTON PUMP INHIBITOR PRODUCTS
    • MARKET SIZE AND GROWTH
      • TABLE 23: GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 5: GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • LAXATIVES
      • TABLE 24: PHARMACOLOGIC MANAGEMENT OF CHRONIC CONSTIPATION IN THE U.S.
      • TABLE 25: MARKETED LAXATIVE PRODUCTS
      • TABLE 26: PHARMACOLOGIC MANAGEMENT OF CHRONIC CONSTIPATION (IN AND OUTSIDE THE U.S.)
    • MARKET SIZE AND GROWTH
      • TABLE 27: GLOBAL PRESCRIPTION LAXATIVE MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 6: GLOBAL PRESCRIPTION LAXATIVE MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • BOWEL ANTI-INFLAMMATORY
      • TABLE 28: MARKETED ANTI-INFLAMMATORY BOWEL PRODUCTS
    • MARKET SIZE AND GROWTH
      • TABLE 29: GLOBAL MARKET FOR PRESCRIPTION BOWEL ANT-INFLAMMATORIES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 7: GLOBAL MARKET FOR PRESCRIPTION BOWEL ANTI-INFLAMMATORIES, BY REGION, 2015-2021 ($ MILLIONS)
  • OTHER GI DRUGS
    • MARKET SIZE AND GROWTH
      • TABLE 30: GLOBAL MARKET FOR OTHER PRESCRIPTION GASTROINTESTINAL THERAPIES, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 8: GLOBAL MARKET FOR OTHER PRESCRIPTION GASTROINTESTINAL THERAPIES, BY REGION, 2015-2021 ($ MILLIONS)

CHAPTER 6 - OTC THERAPY MARKET

  • ANTACIDS
    • SYSTEMIC ANTACIDS
      • Sodium Bicarbonate
    • NONSYSTEMIC ANTACIDS
      • Calcium Carbonate
      • Aluminum Products
      • Magnesium Products
      • Combination Products
        • TABLE 31: KEY BRANDS OF ANTACIDS IN U.S. AND OTHER MARKETS
    • MARKET SIZE AND GROWTH
      • TABLE 32: GLOBAL OTC ANTACID MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 9: GLOBAL OTC ANTACID MARKET, BY REGION, 2015-2021 ($ MILLIONS)
  • LOCALLY ACTING ANTIDIARRHEALS
    • INTESTINAL FLORA MODIFIERS
      • TABLE 33: MARKETED OTC ANTIDIARRHEAL PRODUCTS
    • MARKET SIZE AND GROWTH
      • TABLE 34: GLOBAL OTC ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 10 GLOBAL OTC ANTIDIARRHEAL MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • H2 INHIBITORS
      • TABLE 35: MARKETED OTC H2 INHIBITOR PRODUCTS
    • MARKET SIZE AND GROWTH
      • TABLE 36: GLOBAL MARKET FOR OTC H2 INHIBITORS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 11: GLOBAL MARKET FOR OTC H2 INHIBITORS, BY REGION, 2015-2021 ($ MILLIONS)
  • PROTON PUMP INHIBITORS
    • OMEPRAZOLE (PRILOSEC, PROCTER & GAMBLE)
      • TABLE 37: MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS
    • MARKET SIZE AND GROWTH
      • TABLE 38: GLOBAL MARKET FOR OTC PROTON PUMP INHIBITORS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 12: GLOBAL MARKET FOR OTC PROTON PUMP INHIBITORS, BY REGION, 2015-2021 ($ MILLIONS)
    • LAXATIVES
      • TABLE 39: MARKETED OTC LAXATIVE PRODUCTS
    • MARKET SIZE AND GROWTH
      • TABLE 40: GLOBAL OTC LAXATIVE MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 13: GLOBAL OTC LAXATIVE MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • TOTAL OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH
      • TABLE 41: GLOBAL MARKET FOR OTC GASTROINTESTINAL DRUGS, BY PRODUCT CATEGORY, THROUGH 2021 ($ MILLIONS)
      • FIGURE 14: GLOBAL MARKET FOR OTC GASTROINTESTINAL DRUGS, BY PRODUCT CATEGORY, 2015-2021 ($ MILLIONS)

CHAPTER 7 - DIAGNOSTICS AND DEVICES MARKET

  • ENTERIC DISEASE TESTING METHODS
    • TABLE 42: ENTERIC DISEASE TESTING METHODS
    • TABLE 43: ENTERIC DISEASE DIAGNOSTICS, BY DISEASE TYPE
  • GLOBAL MARKET FOR ENTERIC DIAGNOSTIC TESTS
    • TABLE 44: GLOBAL MARKET FOR DIAGNOSTICS FOR GI DISEASES, BY TYPE, THROUGH 2021 ($ MILLIONS)
    • FIGURE 15: GLOBAL MARKET FOR DIAGNOSTICS FOR GI DISEASES, BY TYPE, 2015-2021 ($ MILLIONS)
  • CAMPYLOBACTER
    • FILMARRAY GASTROINTESTINAL (GI) PANEL
      • TABLE 45: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR CAMPYLOBACTER AND SALMONELLA
    • MARKET SIZE AND GROWTH
      • TABLE 46: GLOBAL MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, BY REGION,THROUGH 2021 ($ MILLIONS)
      • FIGURE 16: GLOBAL MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
  • NOROVIRUS
    • LABORATORY TESTS
    • IMMUNOLOGICAL TESTS
    • ELISA
    • RT-QPCR ASSAYS
    • CONVENTIONAL RT-PCR ASSAYS FOR GENOTYPING
    • ENZYME IMMUNOASSAYS
    • MULTIPLEX TESTING
      • TABLE 47: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR NOROVIRUSES
      • Multiplex PCRs
      • Luminex Multiplex PCR
    • FOODPROOF NOROVIRUS DETECTION KIT (GI, GII, GIV)
      • Next-Generation Sequencing (NGS)
    • MARKET SIZE AND GROWTH
      • TABLE 48: GLOBAL MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 17: GLOBAL MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
  • ROTAVIRUS
  • LUMINEX GASTROINTESTINAL PATHOGEN PANEL
    • TABLE 49: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR ROTAVIRUS
  • MARKET SIZE AND GROWTH
    • TABLE 50: GLOBAL MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 18: GLOBAL MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
  • GIARDIA PARASITE
    • REVERSE TRANSCRIPTASE PCR
    • HIGH-RESOLUTION MELT CURVE ANALYSIS
    • PCR-RESTRICTION FRAGMENT LENGTH POLYMORPHISM
    • SINGLE-STRAND CONFORMATION POLYMORPHISM
    • PCR-REVERSE LINE BLOT ASSAY
      • TABLE 51: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR GIARDIA PARASITE
    • MARKET SIZE AND GROWTH
      • TABLE 52: GLOBAL MARKET FOR GIARDIA PARASITE DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 19: GLOBAL MARKET FOR GIARDIA PARASITE DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • E. COLI
      • TABLE 53: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR E. COLI
    • MARKET SIZE AND GROWTH
      • TABLE 54: GLOBAL MARKET FOR E. COLI DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 20: GLOBAL MARKET FOR E. COLI DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
  • CRYPTOSPORIDIUM
    • ACID-STAINING TEST
      • TABLE 55: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR CRYPTOSPORIDIUM
    • MARKET SIZE AND GROWTH
      • TABLE 56: GLOBAL MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 21: GLOBAL MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • SHIGELLA
      • TABLE 57: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR SHIGELLA
    • MARKET SIZE AND GROWTH
      • TABLE 58: GLOBAL MARKET FOR SHIGELLA DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 22: GLOBAL MARKET FOR SHIGELLA DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • TYPHOID
      • TABLE 59: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR SALMONELLA
    • MARKET SIZE AND GROWTH
      • TABLE 60: GLOBAL MARKET FOR TYPHOID DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 23: GLOBAL MARKET FOR TYPHOID DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • AMEBIASIS
      • TABLE 61: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR AMEBIASIS
    • MARKET SIZE AND GROWTH
      • TABLE 62: GLOBAL MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 24: GLOBAL MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • CHOLERA
      • TABLE 63: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR CHOLERA
    • MARKET SIZE AND GROWTH
      • TABLE 64: GLOBAL MARKET FOR CHOLERA DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 25: GLOBAL MARKET FOR CHOLERA DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • OTHER (H. PYLORI, YERSINIA) DIAGNOSTIC TESTS
      • TABLE 65: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR H. PYLORI
    • MARKET SIZE AND GROWTH
      • TABLE 66: GLOBAL MARKET FOR OTHER (SALMONELLA, H. PYLORI) DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 26: GLOBAL MARKET FOR OTHER (SALMONELLA, H. PYLORI) DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • MEDICAL DEVICES (ENDOSCOPY)
      • TABLE 67: EMERGING NOVEL DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC TECHNIQUES
    • NEW DIAGNOSTIC ENDOSCOPIC TECHNIQUES
      • Endoscopic Ultrasound
      • Radio-controlled, Motor-driven Capsule (Robotic Endoscopy)
    • NEW TECHNOLOGY IN THERAPY OF GI CANCERS
      • Natural Orifice Transluminal Endoscopic Surgery (NOTES) Technique
      • Per-oral Endoscopic Myotomy
      • Endoscopic Mucosal Resection
      • Radiofrequency Ablation
    • MARKET SIZE AND GROWTH
      • TABLE 68: GLOBAL MARKET FOR MEDICAL DEVICES (ENDOSCOPY), BY REGION, THROUGH 2021 ($ MILLIONS)
      • FIGURE 27: GLOBAL MARKET FOR MEDICAL DEVICES (ENDOSCOPY), BY REGION, 2015-2021 ($ MILLIONS)
    • MARKET SIZE AND GROWTH
      • TABLE 69: GLOBAL MARKET FOR GASTRO-DIAGNOSTICS, THROUGH 2021 ($ MILLIONS)
        • FIGURE 28: GLOBAL MARKET FOR GASTRO-DIAGNOSTICS, 2015-2021 ($ MILLIONS)

CHAPTER 8 - GASTROINTESTINAL PRODUCT PIPELINE

  • THERAPIES FOR TREATING GASTRIC CANCER
    • RAMUCIRUMAB (LY3009806)
    • RG1273 (RO4368451)
    • TAS-118
    • KEYTRUDA (PEMBROLIZUMAB)
    • AVELUMAB (PF 06834635)
    • PERTUZUMAB
      • TABLE 70: DEVELOPMENTAL PIPELINE OF GI THERAPIES
  • GERD AND PEPTIC ULCERS
    • VONOPRAZAN (TAK-438)
    • THERAPIES FOR TREATING IBS
    • LINACLOTIDE
    • IBODUTANT
    • PLECANATIDE
    • TENAPANOR
    • ALOSETRON
  • THERAPIES FOR TREATING ULCERATIVE COLITIS AND CROHN'S DISEASE
    • ETROLIZUMAB
    • OZANIMOD
    • XELJANZ (TOFACITINIB)
    • TAK-114
    • LY3074828
    • GED 0301 (MONGERSEN)

CHAPTER 9 - PATENTS

  • TABLE 71: PATENTS ISSUED
  • TABLE 72: PATENTS APPLIED

CHAPTER 10 - COMPANY PROFILES

  • ALLERGAN PLC
  • ARDELYX INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA
  • CELGENE CORP.
  • CLOVIS ONCOLOGY
  • DAEWOONG PHARMACEUTICAL CO., LTD.
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE
  • HORIZON PHARMA PLC
  • IMMUNOGENX
  • IMMUNOMEDICS
  • MERCK & CO.
  • MERRIMACK PHARMACEUTICALS INC.
  • NEW LINK GENETICS
  • OTSUKA HOLDINGS CO. LTD.
  • PFIZER INC.
  • ROCHE
  • SANOFI
  • SHIRE
  • SUCAMPO PHARMACEUTICALS INC.
  • SYNERGY PHARMACEUTICALS INC.
  • SYNTHETIC BIOLOGICS
  • TAIHO PHARMACEUTICAL CO., LTD.
  • TAKEDA PHARMACEUTICALS
  • VALEANT PHARMACEUTICALS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR GASTROINTESTINAL DISORDER THERAPEUTICS AND DIAGNOSTICS, BY CATEGORY, THROUGH 2021 ($ MILLIONS)
    • TABLE 1: U.S. INCIDENCE OF INDIVIDUAL PATHOGENS
    • TABLE 2: ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GI CONDITIONS IN THE U.S.
    • TABLE 3: GASTRIC CANCER PREVALENCE, 2012-2021 (THOUSANDS)
    • TABLE 4: PREVALENCE ESTIMATES OF IBD, BY COUNTRY (%)
    • TABLE 5: U.S. PREVALENCE OF INFLAMMATORY BOWEL DISEASE (NUMBER OF CASES PER 100,000 POPULATION)
    • TABLE 6: U.S. INCIDENCE OF INFLAMMATORY BOWEL DISEASE (NUMBER OF NEWLY DIAGNOSED CASES PER 100,000 PERSON-YEARS)
    • TABLE 7: GLOBAL PREVALENCE OF INFLAMMATORY BOWEL DISEASE
    • TABLE 8: COMMONLY USED LAXATIVE AGENTS
    • TABLE 9: PREVALENCE OF GERD SYMPTOMS (%)
    • TABLE 10: U.S. STATES THAT PROVIDE COMPLETE RANGE OF COLORECTAL DIAGNOSTIC SCREENING
    • TABLE 11: GLOBAL MARKET FOR PRESCRIPTION GI THERAPIES, BY CATEGORY, THROUGH 2021 ($ MILLIONS)
    • TABLE 12: KEY ANTI-DIARRHEAL BRANDS
    • TABLE 13: GLOBAL MARKET FOR PRESCRIPTION ANTIDIARRHEAL THERAPIES, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 14: ANTIEMETICS: SITE OF ACTION AND EXAMPLES
    • TABLE 15: MARKETED ANTIEMETIC PRODUCTS
    • TABLE 16: GLOBAL MARKET FOR PRESCRIPTION ANTIEMETIC THERAPIES, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 17: MARKETED GASTROINTESTINAL CANCER PRODUCTS
    • TABLE 18: GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER THERAPIES, BY REGION, THROUGH 2021 ($ MILLIONS
    • TABLE 19: MARKETED H2 INHIBITOR PRODUCTS
    • TABLE 20: GLOBAL PRESCRIPTION H2 INHIBITOR MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 21: PROTON PUMP INHIBITORS: THERAPY AND PH
    • TABLE 22: MARKETED PROTON PUMP INHIBITOR PRODUCTS
    • TABLE 23: GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 24: PHARMACOLOGIC MANAGEMENT OF CHRONIC CONSTIPATION IN THE U.S.
    • TABLE 25: MARKETED LAXATIVE PRODUCTS
    • TABLE 26: PHARMACOLOGIC MANAGEMENT OF CHRONIC CONSTIPATION (IN AND OUTSIDE THE U.S.)
    • TABLE 27: GLOBAL PRESCRIPTION LAXATIVE MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 28: MARKETED ANTI-INFLAMMATORY BOWEL PRODUCTS
    • TABLE 29: GLOBAL MARKET FOR PRESCRIPTION BOWEL ANT-INFLAMMATORIES, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 30: GLOBAL MARKET FOR OTHER PRESCRIPTION GASTROINTESTINAL THERAPIES, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 31: KEY BRANDS OF ANTACIDS IN U.S. AND OTHER MARKETS
    • TABLE 32: GLOBAL OTC ANTACID MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 33: MARKETED OTC ANTIDIARRHEAL PRODUCTS
    • TABLE 34: GLOBAL OTC ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 35: MARKETED OTC H2 INHIBITOR PRODUCTS
    • TABLE 36: GLOBAL MARKET FOR OTC H2 INHIBITORS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 37: MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS
    • TABLE 38: GLOBAL MARKET FOR OTC PROTON PUMP INHIBITORS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 39: MARKETED OTC LAXATIVE PRODUCTS
    • TABLE 40: GLOBAL OTC LAXATIVE MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 41: GLOBAL MARKET FOR OTC GASTROINTESTINAL DRUGS, BY PRODUCT CATEGORY, THROUGH 2021 ($ MILLIONS)
    • TABLE 42: ENTERIC DISEASE TESTING METHODS
    • TABLE 43: ENTERIC DISEASE DIAGNOSTICS, BY DISEASE TYPE
    • TABLE 44: GLOBAL MARKET FOR DIAGNOSTICS FOR GI DISEASES, BY TYPE, THROUGH 2021 ($ MILLIONS)
    • TABLE 45: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR CAMPYLOBACTER AND SALMONELLA
    • TABLE 46: GLOBAL MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, BY REGION,THROUGH 2021 ($ MILLIONS)
    • TABLE 47: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR NOROVIRUSES
    • TABLE 48: GLOBAL MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 49: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR ROTAVIRUS
    • TABLE 50: GLOBAL MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 51: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR GIARDIA PARASITE
    • TABLE 52: GLOBAL MARKET FOR GIARDIA PARASITE DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 53: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR E. COLI
    • TABLE 54: GLOBAL MARKET FOR E. COLI DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 55: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR CRYPTOSPORIDIUM
    • TABLE 56: GLOBAL MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 57: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR SHIGELLA
    • TABLE 58: GLOBAL MARKET FOR SHIGELLA DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 59: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR SALMONELLA
    • TABLE 60: GLOBAL MARKET FOR TYPHOID DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 61: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR AMEBIASIS
    • TABLE 62: GLOBAL MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 63: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR CHOLERA
    • TABLE 64: GLOBAL MARKET FOR CHOLERA DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 65: COMMERCIALLY AVAILABLE MOLECULAR TESTS FOR H. PYLORI
    • TABLE 66: GLOBAL MARKET FOR OTHER (SALMONELLA, H. PYLORI) DIAGNOSTIC TESTS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 67: EMERGING NOVEL DIAGNOSTIC AND THERAPEUTIC ENDOSCOPIC TECHNIQUES
    • TABLE 68: GLOBAL MARKET FOR MEDICAL DEVICES (ENDOSCOPY), BY REGION, THROUGH 2021 ($ MILLIONS)
    • TABLE 69: GLOBAL MARKET FOR GASTRO-DIAGNOSTICS, THROUGH 2021 ($ MILLIONS)
    • TABLE 70: DEVELOPMENTAL PIPELINE OF GI THERAPIES
    • TABLE 71: PATENTS ISSUED
    • TABLE 72: PATENTS APPLIED

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR GASTROINTESTINAL DISORDER THERAPEUTICS AND DIAGNOSTICS, BY CATEGORY, 2015-2021 ($ MILLIONS)
    • FIGURE 1: GLOBAL MARKET FOR PRESCRIPTION ANTIDIARRHEAL THERAPIES, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 2: GLOBAL MARKET FOR PRESCRIPTION ANTIEMETIC THERAPIES, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 3: GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER THERAPIES, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 4: GLOBAL PRESCRIPTION H2 INHIBITOR MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 5: GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 6: GLOBAL PRESCRIPTION LAXATIVE MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 7: GLOBAL MARKET FOR PRESCRIPTION BOWEL ANTI-INFLAMMATORIES, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 8: GLOBAL MARKET FOR OTHER PRESCRIPTION GASTROINTESTINAL THERAPIES, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 9: GLOBAL OTC ANTACID MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 10: GLOBAL OTC ANTIDIARRHEAL MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 11: GLOBAL MARKET FOR OTC H2 INHIBITORS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 12: GLOBAL MARKET FOR OTC PROTON PUMP INHIBITORS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 13: GLOBAL OTC LAXATIVE MARKET, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 14: GLOBAL MARKET FOR OTC GASTROINTESTINAL DRUGS, BY PRODUCT CATEGORY, 2015-2021 ($ MILLIONS)
    • FIGURE 15: GLOBAL MARKET FOR DIAGNOSTICS FOR GI DISEASES, BY TYPE, 2015-2021 ($ MILLIONS)
    • FIGURE 16: GLOBAL MARKET FOR CAMPYLOBACTER DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 17: GLOBAL MARKET FOR NOROVIRUS DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 18: GLOBAL MARKET FOR ROTAVIRUS DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 19: GLOBAL MARKET FOR GIARDIA PARASITE DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 20: GLOBAL MARKET FOR E. COLI DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 21: GLOBAL MARKET FOR CRYPTOSPORIDIUM DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 22: GLOBAL MARKET FOR SHIGELLA DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 23: GLOBAL MARKET FOR TYPHOID DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 24: GLOBAL MARKET FOR AMEBIASIS DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 25: GLOBAL MARKET FOR CHOLERA DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 26: GLOBAL MARKET FOR OTHER (SALMONELLA, H. PYLORI) DIAGNOSTIC TESTS, BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 27: GLOBAL MARKET FOR MEDICAL DEVICES (ENDOSCOPY), BY REGION, 2015-2021 ($ MILLIONS)
    • FIGURE 28: GLOBAL MARKET FOR GASTRO-DIAGNOSTICS, 2015-2021 ($ MILLIONS)
Back to Top